sarafloxacin has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bodey, GP; Ho, DH; LeBlanc, B; Rolston, K | 1 |
| Bodey, GP; Ho, DH; LeBlanc, B; Rolston, KV | 2 |
3 other study(ies) available for sarafloxacin and Neoplasms
| Article | Year |
|---|---|
In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms | 1988 |
In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Quinones; Sepsis | 1987 |
In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gram-Negative Bacteria; Humans; Naphthyridines; Neoplasms; Quinolizines | 1987 |